NCT05556239Completed
STAY-STRONG Study of Exercise Training During Chemotherapy
The Effect of Resistance Training in Patients With Malignant Lymphoma Undergoing Chemotherapy Treatment - the STAY STRONG TRIAL - a Randomized Controlled Trial.
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
This study evaluates the effectiveness of a supervised progressive resistance training program in patients malignant lymphomas with the primary outcome being lean body mass. The study is designed as a a single center, two-armed, parallel-group, investigator-initiated clinical randomized controlled superiority trail evaluating the effectiveness of a 4-month supervised progressive resistance training intervention compared to usual care.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 42 (actual)
- First submitted
- 22 Sept 2022
- Start date
- 25 Oct 2022
- Primary completion date
- 1 Oct 2024
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- NCT number
- NCT05556239
What you commit to
- Study type: Interventional
- Participants enrolled: 42
- From 25 Oct 2022 to the primary completion date, 1 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with:
- Clinically significant cardiovascular disease, including, but not limited to: Heart failure NYHA (New York Heart Association) class III-IV, uncontrolled hypertension, and symptomatic cardiac arrhythmias.
- Psychiatric, neurological, or geographical conditions that could influence protocol adherence.
- Disorders that cause an inability to perform exercise training for one hour.
- Any other known malignancy requiring active treatment.
Who the study is looking for
- Participants must:
- Be newly diagnosed with diffuse large B-cell lymphoma and Hodgkin Lymphoma
- Be expected to receive treatment with an anthracycline-containing combination chemotherapy at the Department of Hematology, Rigshospitalet
- Be ≥ 18 years of age at the time of signing the informed consent form.
- Be residing in Denmark
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2
- Be able to speak and read Danish, and to provide a signed informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rigshospitalet Coordinator of this site? Confirm its status | Copenhagen | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.